{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 39,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/23",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.48,
        "x": 0.518,
        "y": 0.35
      },
      "kind": "list",
      "text": "Ongoing Discussions with Potential ROW Partners; Latin America remains a significant commercial opportunity; EU authorization, if granted, can be used to enable access in many other countries; Clinical Trial Transition Underway; New open-label trial to provide continued access for study patients in one streamlined, cost-effective study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45c76acc-f00f-487c-9186-a591f1e748ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.48,
        "x": 0.038,
        "y": 0.35
      },
      "kind": "list",
      "text": "MAA Under Review by EMA; MAA filing accepted in August 2022; Potential decision on approval in late 2023; Manufacturing in place to support commercialization in Europe and Middle East; Continuing to engage with FDA to identify potential path towards BLA resubmission; Refusal to File (RTF) Received for BLA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cee14475-6f64-46ba-8fcb-ae6f9483d342",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.518,
        "y": 0.236
      },
      "kind": "paragraph",
      "text": "Next Steps",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "274bed0e-d53b-4b52-a550-f54dde043447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.038,
        "y": 0.236
      },
      "kind": "paragraph",
      "text": "Regulatory Status",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db31415b-fd00-472d-a1f1-6ae826a78695",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.446,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Regulatory and Program Status",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c080d4e-4ad3-48e1-84c7-b0bf38d2bd48",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}